PAUL HOPKINS to Hypolipidemic Agents
This is a "connection" page, showing publications PAUL HOPKINS has written about Hypolipidemic Agents.
Connection Strength
0.552
-
A family-specific linkage analysis of blood lipid response to fenofibrate in the Genetics of Lipid Lowering Drug and Diet Network. Pharmacogenet Genomics. 2015 Oct; 25(10):511-4.
Score: 0.111
-
Genetic analysis of 16 NMR-lipoprotein fractions in humans, the GOLDN study. Lipids. 2013 Feb; 48(2):155-65.
Score: 0.091
-
Genome-wide association study indicates variants associated with insulin signaling and inflammation mediate lipoprotein responses to fenofibrate. Pharmacogenet Genomics. 2012 Oct; 22(10):750-7.
Score: 0.090
-
The effect of CYP7A1 polymorphisms on lipid responses to fenofibrate. J Cardiovasc Pharmacol. 2012 Mar; 59(3):254-9.
Score: 0.086
-
A genome-wide association study of inflammatory biomarker changes in response to fenofibrate treatment in the Genetics of Lipid Lowering Drug and Diet Network. Pharmacogenet Genomics. 2012 Mar; 22(3):191-7.
Score: 0.086
-
The genetic architecture of fasting plasma triglyceride response to fenofibrate treatment. Eur J Hum Genet. 2008 May; 16(5):603-13.
Score: 0.065
-
Variants identified in a GWAS meta-analysis for blood lipids are associated with the lipid response to fenofibrate. PLoS One. 2012; 7(10):e48663.
Score: 0.023